Stereotaxis, Inc. (NYSEAMERICAN:STXS – Get Free Report) was the target of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 2,540,000 shares, a drop of 17.3% from the November 15th total of 3,070,000 shares. Based on an average daily volume of 291,600 shares, the short-interest ratio is presently 8.7 days. Currently, 3.6% of the company’s shares are short sold.
Hedge Funds Weigh In On Stereotaxis
A number of hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in Stereotaxis in the third quarter worth approximately $39,000. Forum Financial Management LP bought a new position in shares of Stereotaxis during the 2nd quarter worth approximately $48,000. Jane Street Group LLC grew its position in shares of Stereotaxis by 26.9% during the 3rd quarter. Jane Street Group LLC now owns 29,773 shares of the company’s stock worth $61,000 after buying an additional 6,313 shares during the period. Rhumbline Advisers increased its stake in shares of Stereotaxis by 645.6% in the 2nd quarter. Rhumbline Advisers now owns 48,251 shares of the company’s stock valued at $88,000 after acquiring an additional 41,780 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Stereotaxis by 449.9% during the 3rd quarter. Barclays PLC now owns 101,953 shares of the company’s stock valued at $208,000 after acquiring an additional 83,412 shares during the period. Institutional investors own 45.35% of the company’s stock.
Stereotaxis Stock Up 6.8 %
Shares of STXS opened at $2.34 on Friday. Stereotaxis has a 1 year low of $1.63 and a 1 year high of $3.29.
Stereotaxis Company Profile
Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.
Further Reading
- Five stocks we like better than Stereotaxis
- Why Invest in 5G? How to Invest in 5G Stocks
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Dividend Capture Strategy: What You Need to Know
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.